Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TAA-T

Phase 1Biologic

CCatherine Bollard

TAA-T is one of 21 biologic programs targeting Brain Tumor. It is currently in Phase 1.

2

Indications

2

Total Trials

2

Active Trials

20

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain TumorActive, not recruiting

Hodgkin LymphomaActive, not recruiting

Brain TumorPhase 1

Active, not recruiting

Hodgkin LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hodgkin Lymphoma

#DrugCompanyPhaseTrials

DTIC-Dome

Opdivo

Bristol-Myers Squibb

Adcetris

Velban

Adriamycin

Adriamycin

Keytruda

Gemzar

Johnson & Johnson

Beyfortus

Navelbine

PPierre Fabre Medicament

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Hodgkin Lymphoma

NCT03843294

Q4 2028

Phase 1Active, not recruiting

Brain Tumor

NCT03652545

Clinical

Trials by Indication[1]

Hodgkin Lymphoma1 trial

Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma

Active, not recruiting·CCatherine Bollard·Phase 1·NCT03843294·18 enrolled

Brain Tumor1 trial

Phase I REsearch on Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

Active, not recruiting·CCatherine Bollard·Phase 1·NCT03652545·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TAA-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAA-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAA-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Catherine Bollard company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCatherine Bollard

Related News